ABSTRACT
No information is currently available on the safety of the aminoglycoside ribostamycin in pregnancy. We aimed to study the pregnancy outcome of women inadvertently exposed to ribostamycin during the first trimester of pregnancy. In a prospective cohort study, 102 women inadvertently exposed to ribostamycin during the first trimester of pregnancy and an age- and gravidity-matched control group, were enrolled. Study outcomes were gestational age at birth, major and minor malformations, and birth weight. Fetal outcomes were evaluated in 85 women inadvertently exposed to ribostamycin during the first-trimester of pregnancy and in 170 control subjects. Newborns were clinically examined at birth by a neonatologist and by imaging studies if any suspicious abnormalities were noted. There were 4/85 (4.9%) babies born with major malformations in the exposed group and 3/170 (1.8%) in the control group (P=0.7). Gestational age at delivery, rate of minor anomalies, rate of preterm births, and birth weight were not different between groups. In conclusion, similar to what is reported for other aminoglycoside, exposure to ribostamycin during the first-trimester of pregnancy does not appear to increase the risk of adverse fetal outcomes.
Subject(s)
Anti-Bacterial Agents/adverse effects , Maternal Exposure , Pregnancy Outcome , Ribostamycin/adverse effects , Abnormalities, Drug-Induced/etiology , Adult , Birth Weight/drug effects , Case-Control Studies , Female , Gestational Age , Humans , Infant, Newborn , Pregnancy , Pregnancy Trimester, First , Prospective Studies , Risk AssessmentABSTRACT
Twelve strains of a rapidly growing Mycobacterium species were isolated from an outbreak associated with intramuscular injections of an antimicrobial agent and were identified by comparative sequence analysis of rpoB and hsp65. These isolates were identified as Mycobacterium massiliense (100% similarity).
Subject(s)
Disease Outbreaks , Injections, Intramuscular/adverse effects , Mycobacterium Infections/epidemiology , Mycobacterium Infections/microbiology , Mycobacterium/isolation & purification , Ribostamycin/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Bacterial Proteins/genetics , Chaperonin 60 , Chaperonins/genetics , Child , Child, Preschool , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , DNA-Directed RNA Polymerases/genetics , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Mycobacterium/genetics , Phylogeny , Ribostamycin/administration & dosage , Ribostamycin/therapeutic use , Sequence Analysis, DNASubject(s)
Anaphylaxis/immunology , Anti-Bacterial Agents/adverse effects , Drug Hypersensitivity/immunology , Ribostamycin/adverse effects , Adult , Anaphylaxis/chemically induced , Anti-Bacterial Agents/immunology , Drug Hypersensitivity/etiology , Female , Humans , Pelvic Inflammatory Disease/drug therapy , Recurrence , Ribostamycin/immunologyABSTRACT
A 48-year-old man became erythrodermatous after intramuscular administration of ribostamycin, an aminoglycoside antibiotic in the same family as neomycin. Patch tests were positive to ribostamycin and neomycin, as well as to mercurials. There was no mercurial preservative in the injection solution. A lymphocyte transformation test was positive for ribostamycin and tobramycin, but not for gentamycin. Diagnostic and structure-activity relationship aspects of the case are discussed.